Close

TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology

As a global contract research organization, Creative Biolabs established one-stop CAR-T cell therapy development solutions to advance your CAR-T cell product candidate. We offer comprehensive solutions distinctly for the progressive biopharma venture. To build more powerful CAR-T cells, we have developed TRAC-CAR T cell with CRISPR/Cas9 technology.

Challenges for Conventional CAR-T Cell

TRAC CAR T Cell Development with CRISPR Cas9 Technology

CAR-T cell therapy has shown significant efficacy in the treatment of acute leukemia and non-hodgkin lymphoma, etc., thus considering to be one of the most promising cancer immunotherapies. While some existing disadvantages need to be improved for making more efficient CAR-T cells.

For conventional CAR-T cells, CAR genes are transferred into the T cell genome by retroviruses or lentiviruses. They can cause CAR genes to be randomly inserted into the locus of genome which may elicit potential genetic side effects.

CRISPR/Cas9 Technology

RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/Cas9 has demonstrated great potential for precise genetic manipulation. CRISPR/Cas9 has significantly hit the headlines as a powerful tool that is dramatically changing the way scientists are advancing researches. CRISPR technology can deliver a CAR gene to a very specific location (TRAC) in the genome of the T cell. This precise approach resulted in CAR T cells with more stamina.

Advantages of CRISPR/Cas9 Technology

  • Cost effective,
  • Integration-free,
  • Capacity for mutating multiple genes in a single system

TRAC-CAR-T Cell Development Services

TRAC CAR T Cell Development with CRISPR Cas9 Technology Fig.1 RISPR/Cas9-targeted CAR gene integration into the TRAC locus. (Eyquemc, 2017) Utilizing the CRISPR/Cas9 technology that holds great promise as an efficient gene knock-in platform, we have developed end-to-end CRISPR/Cas9 services to directing the specific CARs to the T-cell receptor α constant (TRAC) locus (see Fig.1). Compared with conventional CAR T cells, TRAC-CAR T cells exhibit uniform CAR expression which results in enhanced T cell potency and safety profile. Our TRAC-CAR T platform will advance your desired immunotherapies through CRISPR/Cas9 genome editing which is more precise. Leverage the CRISPR to build CAR T cells, the genomic engines will run more smoothly, which means TRAC-CAR T cells rack up more trouble-free miles with long-distance races.

CRISPR/Cas9 Service Process

TRAC CAR T Cell Development with CRISPR Cas9 Technology

NR4A Knock Out CAR-T Cell Development with CRISPR Technology

Leverage the expertise of our experienced scientists to expedite and innovate your therapeutic CAR-T projects, we are inspired by NR4A target and are dedicated to providing NR4A knock out CAR-T cell development services.

TRAC-CAR-T Cell Advantages

TRAC CAR T Cell Development with CRISPR Cas9 Technology
  • Expressed CARs homogeneously and consistently at an optimal baseline level that offered improved antitumor efficacy,
  • Reduced tonic activation signaling and developed effective internalization and balanced re-expression of the CAR upon single or repeated antigen exposure,
  • Retained a naive/central memory phenotype, delayed effector T cell differentiation and exhaustion, making them better effector cells,
  • Improved safety profile. (Because the lack of TCRs reduces the risk of TCR-induced alloreactivity and autoimmunity, and the precisec insertion of the CAR coding sequence reduces the risk for insertional oncogenesis.)

To accelerate your CAR-T project, develop engineered T cell with precise CAR insertion, Creative Biolabs offers an end-to-end CRISPR/Cas9 solution that holds immense promise for advancing immunotherapy. We combine the traditional and the most advanced CRISPR/Cas9 genetic manipulation technology to efficiently produce more powerful CAR-T cells addressing urgent unmet medical demands. Please feel free to contact us to learn how we can be involved in your project.

Reference

  1. Eyquem, Justin, et al. "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection." Nature 543.7643 (2017): 113.

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.